The short version of AOD-9604 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-19 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
The Transitional Federal Government (TFG) was the internationally recognised government of Somalia until 20 August 2012, when its tenure officially ended. It was established as one of the Transitional Federal Institutions (TFIs) of government as defined in the Transitional Federal Charter (TFC) adopted in November 2004 by the Transitional Federal Parliament (TFP). The Transitional Federal Government officially comprised the executive branch of government, with the TFP serving as the legislative branch. The government was headed by the President of Somalia, to whom the cabinet reported through the Prime Minister. However, it was also used as a general term to refer to all three branches collectively. Owing to a lack of funding and human resources, an arms embargo that made it difficult to reestablish a national security force, and general indifference on the part of the international community, Yusuf found himself obliged to deploy thousands of troops from Puntland to Mogadishu to sustain the battle against insurgent elements in the southern part of the country. Financial support for this effort was provided by the autonomous region's government. This left little revenue for Puntland's own security forces and civil service employees, leaving the territory vulnerable to piracy and terrorist attacks. On 29 December 2008, Yusuf announced before a united parliament in Baidoa his resignation as President of Somalia.
The first to be identified was the use of NAD+ as the ADP-ribose donor in ADP-ribosylation reactions, observed in the early 1960s. Studies in the 1980s and 1990s revealed the activities of NAD+ and NADP+ metabolites in cell signaling – such as the action of cyclic ADP-ribose, which was discovered in 1987. The metabolism of NAD+ remained an area of intense research into the 21st century, with interest heightened after the discovery of the NAD+-dependent protein deacetylases called sirtuins in 2000, by Shin-ichiro Imai and coworkers in the laboratory of Leonard P. Guarente. In 2009 Imai proposed the "NAD World" hypothesis that key regulators of aging and longevity in mammals are sirtuin 1 and the primary NAD+ synthesizing enzyme nicotinamide phosphoribosyltransferase (NAMPT). In 2016 Imai expanded his hypothesis to "NAD World 2.0", which postulates that extracellular NAMPT from adipose tissue maintains NAD+ in the hypothalamus (the control center) in conjunction with myokines from skeletal muscle cells. In 2018, Napa Therapeutics was formed to develop drugs against a novel aging-related target based on the research in NAD metabolism conducted in the lab of Eric Verdin.
The FDA has issued alerts regarding these risks and also noted reports of angioedema and multi-organ hypersensitivity reactions in postmarketing surveillance. In 2007, the FDA required Cephalon, the manufacturer of Provigil, to modify the Provigil leaflet to include warnings about these serious conditions. The long-term safety and effectiveness of modafinil have not been conclusively established. The FDA does not endorse modafinil for children's medical conditions due to an increased risk of rare but serious dermatological toxicity, manifested as Stevens–Johnson syndrome which is a type of severe skin reaction. However, in Europe, modafinil may be prescribed for treating narcolepsy in children.
Sources: en.wikipedia.org
== Distribution and habitat == Clown loaches are native to the islands of Sumatra and Borneo in Indonesia. Clear stream environments provide the optimal habitat for clown loaches, but biannual monsoon flooding forces the fish to move into flooded flood plains, or murky or blackwater rivers or lakes, for 7–8 months of the year, and clown loaches are commonly found in the flood plains of hilly areas. Breeding adults migrate to smaller waterways to spawn annually. In its native habitat, the fish is found in water with a temperature range of 25 to 30 °C (77 to 86 °F), a pH between 5.0 and 8.0, and water hardness between 5 and 12 dH.
== Physiology and pathophysiology == Beta cells play a paramount role in glucose homeostasis. Progressive loss of insulin secretory capacity is a key defect associated with the transition from a healthy glycaemic state to hyperglycaemia, characteristic of untreated diabetes mellitus. In type 1 diabetes mellitus and pancreatogenic diabetes beta cell destruction is a primary event from the perspective of the feedback loop. In type 2 diabetes beta cell dysfunction is an essential constituent as well, but subsequent to the development of insulin resistance. Other mechanisms, including lipotoxicity, amyloid deposition, oxidative stress, mitochondrial dysfunction, ER stress and inflammation may be involved as well. The beta cell loss in type 2 diabetes is mainly caused by reduced beta cell number rather than size. Hyperglycaemia becomes clinically significant once insulin over-secretion can no longer compensate for the degree of insulin resistance. It remains an unsolved question if impaired pancreatic beta cell function or hypersecretion of insulin represent the primary event in the pathogenesis of type 2 diabetes. Both scenarios may be cause and consequence, and it has been postulated that the direction of causality depends on the respective subtype of diabetes. Therefore, they may be part of a complex feedback loop involving glucose toxicity leading to a biphasic response, thereby preventing neoplastic effects of dynamical compensation by mutant takeover.
== Honours and achievements == Team AFL premiership: 1993, 2000 AFL pre-season premiership: 1994, 2000 McClelland Trophy: 1993, 1999, 2000, 2001 Individual Australian Football Hall of Fame (inducted 2026) All-Australian team: 2000, 2007 Crichton Medal: 2000 AFL Rising Star Nominee: 1993 International Rules Series Player: 2005, 2006, 2010, 2014, 2015
=== Fashions === The term "glabrousness" also has been applied to human fashions, wherein some participate in culturally motivated hair removal by depilation (surface removal by shaving, dissolving), or epilation (removal of the entire hair, such as waxing or plucking). Although the appearance of secondary hair on parts of the human body commonly occurs during puberty, and therefore, is often seen as a symbol of adulthood, removal of this and other hair may become fashionable in some cultures and subcultures. In many modern Western cultures, men are encouraged to shave their beards, and women are encouraged to remove hair growth in various areas. Commonly depilated areas for women are the underarms, legs, and pubic hair. Some individuals depilate the forearms. In recent years, bodily depilation in men has increased in popularity among some subcultures of Western men. For men, the practice of depilating the pubic area is common, especially for aesthetic reasons. Most men will use a razor to shave this area, however, as best practice, it is recommended to use a body trimmer to shorten the length of the hair before shaving it off completely.
Sources: en.wikipedia.org
Toxicology and pharmacology mainly concern the effects of a substance on a multi-cellular lifeform, usually an animal. As a result, anything that is not in vivo is in vitro. This includes animal organ cultures, animal tissue cultures (ex vivo), animal cell cultures, prokaryotic cell cultures, and isolated biomolecules. The study of pathogens treats the pathogen-in-host state as in vivo. (For example, the in vivo transcriptomics of E. coli during a urinary tract infection.) Accordingly, in vitro includes models that do not involve the entire host. Viruses, which only replicate in living cells, are studied in the laboratory in cell or tissue culture, and many animal virologists refer to such work as being in vitro to distinguish it from in vivo work in whole animals. The study of the molecular machineries tends to see the whole cell as the biggest unit. As a result, cell cultures (even mammalian ones) can be considered in vivo instead of the usual assignment as in vitro. In this context, in vitro exclusively refers to cell-free systems.
==== Absorption ==== There has been little research on psilocybin's bioavailability. Its oral bioavailability, as its active form psilocin, was about 55.0% (± ~20%) relative to intravenous administration in one small older study (n=3). After oral administration, psilocybin is detectable in the blood circulation within 20 to 40 minutes, and psilocin is detectable after 30 minutes. The mean time to peak levels for psilocin is 1.05 to 3.71 hours in different studies, with most around 2 hours and the upper limit of 3.71 hours being an outlier. Psilocybin, in terms of psilocin, shows clear linear or dose-dependent pharmacokinetics. Maximal concentrations of psilocin were 11 ng/mL, 17 ng/mL, and 21 ng/mL with oral psilocybin doses of 15, 25, and 30 mg psilocybin, respectively. The maximal levels of psilocin have been found to range from 8.2 ng/mL to 37.6 ng/mL across a dose range of 14 to 42 mg. The dose-normalized peak concentration of psilocin is about 0.8 ng/mL/mg. The interindividual variability in the pharmacokinetics of psilocybin is relatively small. There is a very strong positive correlation between dose and psilocin peak levels (R2 = 0.95). The effects of food on the pharmacokinetics of psilocybin have not been reported and are unknown, but no clear sign of food effects has been observed in preliminary analyses. It has also been said that food might delay absorption, reduce peak levels, and reduce bioavailability.
==== General consensus on use ==== There is consensus amongst stroke specialists that tPA is the standard of care for eligible stroke patients, and benefits outweigh the risks. There is significant debate mainly in the emergency medicine community regarding recombinant tPA's effectiveness in ischemic stroke. The NNT Group on evidence-based medicine concluded that it was inappropriate to combine these twelve trials into a single analysis, because of substantial clinical heterogeneity (i.e., variations in study design, setting, and population characteristics). Examining each study individually, the NNT group noted that two of these studies showed benefit to patients given tPA (and that, using analytical methods that they think flawed); four studies showed harm and had to be stopped before completion; and the remaining studies showed neither benefit nor harm. On the basis of this evidence, the NNT Group recommended against the use of tPA in acute ischaemic stroke. The NNT Group notes that the case for the 3-hour time window arises largely from analysis of two trials: NINDS-2 and subgroup results from IST-3. "However, presuming that early (0-3h) administration is better than later administration (3-4.5h or 4.5-6h) the subgroup results of IST-3 suggest an implausible biological effect in which early administration is beneficial, 3-4.5h administration is harmful, and 4.5-6h administration is again beneficial." Indeed, even the original publication of the IST-3 trial found that time-window effects were not significant predictors of outcome (p=0.61).
The technique of balanced anesthetic has been applied widely with cats and dogs. When general anesthesia is used for cats and dogs, the most common method is inhalant agents because they are both easy to manage and the depth of anesthesia is predictable. The depth of anesthesia can be changed and recovered if some unexpected situation occurs during surgery. Although inhaled anesthetics will cause an unconscious state in which cats and dogs will not recall or perceive pain, the depth of anesthesia may not prevent the variety of reflex reactions to harmful stimuli during the operation. In order to prevent these reflex reactions, it may be required to increase the concentration of inhalant anesthetic agents; higher rates of inhalant administration are associated with higher cardiovascular and respiratory complications. Respiratory depression may result, especially in young patients and those with preexisting systemic disease. This is associated with increased morbidity and mortality. With the balanced anesthetic technique, the low concentration of inhalant anesthetic agents and other medicines used during the operation can alter the perception of painful stimuli. In other words, using balanced anesthetic techniques for cats and dogs can decrease the morbidity and mortality effectively. Therefore, in this situation, using balanced anesthetic techniques in cats and dogs is less risky for operation than using the general anesthesia.
== Side effects == Methyldopa is capable of inducing a number of adverse side effects, which range from mild to severe. Nevertheless, they are generally mild when the dose is less than 1 gram per day. Side effects may include:
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.